After surgery , 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide ( EC ; 90 and 600 mg/m(2 ) , respectively , × four cycles ) , followed by docetaxel ( 100 mg/m(2 ) × four cycles ; EC-T ) or epirubicin plus docetaxel ( ET ; 90 and 75 mg/m(2 ) , respectively , × four cycles ) , followed by capecitabine ( 1,250 mg/m(2 ) twice a day on days 1 to 14 , × four cycles ; ET-X ) ; all regimens were given every 3 weeks .
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. ### Patients And Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery , 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide ( EC ; 90 and 600 mg/m(2 ) , respectively , × four cycles ) , followed by docetaxel ( 100 mg/m(2 ) × four cycles ; EC-T ) or epirubicin plus docetaxel ( ET ; 90 and 75 mg/m(2 ) , respectively , × four cycles ) , followed by capecitabine ( 1,250 mg/m(2 ) twice a day on days 1 to 14 , × four cycles ; ET-X ) ; all regimens were given every 3 weeks . The primary end point was invasive disease-free survival. Secondary end points included safety (with an alopecia-specific study) and overall survival (OS). ### results After a median follow-up of 6.6 years and 297 events, 86% of patients who received EC-T and 82% of those who received ET-X were invasive disease free at 5 years (hazard ratio, 1.30; 95% CI, 1.03 to 1.64; log-rank P = .03). The OS difference between arms was not statistically significant (hazard ratio, 1.13; 95% CI, 0.82 to 1.55; log-rank P = .46). The most frequent grade 3 to 4 adverse events in the EC-T versus ET-X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%). Incomplete scalp hair recovery was more frequent in the EC-T than ET-X arm (30% v 14%), and patients who received EC-T wore wigs significantly longer than those who received ET-X (8.35 v 6.03 months). ### conclusion Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. ### Patients And Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery , 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide ( EC ; 90 and 600 mg/m(2 ) , respectively , × four cycles ) , followed by docetaxel ( 100 mg/m(2 ) × four cycles ; EC-T ) or epirubicin plus docetaxel ( ET ; 90 and 75 mg/m(2 ) , respectively , × four cycles ) , followed by capecitabine ( 1,250 mg/m(2 ) twice a day on days 1 to 14 , × four cycles ; ET-X ) ; all regimens were given every 3 weeks . The primary end point was invasive disease-free survival. Secondary end points included safety (with an alopecia-specific study) and overall survival (OS). ### results After a median follow-up of 6.6 years and 297 events, 86% of patients who received EC-T and 82% of those who received ET-X were invasive disease free at 5 years (hazard ratio, 1.30; 95% CI, 1.03 to 1.64; log-rank P = .03). The OS difference between arms was not statistically significant (hazard ratio, 1.13; 95% CI, 0.82 to 1.55; log-rank P = .46). The most frequent grade 3 to 4 adverse events in the EC-T versus ET-X arms were neutropenia (19% v 10%), with 7% febrile neutropenia across arms; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%). Incomplete scalp hair recovery was more frequent in the EC-T than ET-X arm (30% v 14%), and patients who received EC-T wore wigs significantly longer than those who received ET-X (8.35 v 6.03 months). ### conclusion Invasive disease-free survival, but not OS, was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who received the experimental ET-X regimen. Toxicity profiles differed substantially across arms.

            ### Response:
            epirubicin, cyclophosphamide, docetaxel, epirubicin, docetaxel, capecitabine
            